Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 18;12:6937–6947. doi: 10.2147/IJN.S141407

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Tang et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Dose-dependent inhibition of KC cytokines by compound inhibitors.

Notes: (A) The dose-dependent inhibition effect of compound inhibitors on cytokine TNF-α. (B) The dose-dependent inhibition effect of compound inhibitors on cytokine IL-1β. (C) The dose-dependent inhibition effect of compound inhibitors on cytokine IL-6. KCs were incubated with different endocytosis compound inhibitors for 24 h prior to addition of 200 µg/mL FPA/EPI NPs, and the cytokine inhibition was quantified by fluorometry compared with untreated controls. Data are represented as mean ± SD of five determinations.

Abbreviations: AMR, amiloride; Col, colchicine; CPZ, chlorpromazine; FPA/EPI NPs, epirubicin-loaded folic acid-conjugated pullulan acetate nanoparticles; IL, interleukin; KCs, Kupffer cells; NY, nystatin; PDTC, pyrrolidine dithiocarbamate; TNF-α, tumor necrosis factor.